Top of this page
Skip navigation, go straight to the content
R&D pipeline
The UCB pipeline delivers:
- a promising portfolio targeting severe diseases and addressing unmet medical needs
- focus on neurological and immunological diseases
- more convenient and effective treatments for patients and specialists.
UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.
Small molecule drug / NCE
Antibody-based drug / NBE
| Neurology | Indications | Phase 1 | Phase 2 | Phase 3 | Filed | |
|---|---|---|---|---|---|---|
| padsevonil / UCB0942 (PPSI) | epilepsy – highly drug resistant |  | ||||
UCB0599 | Parkinson's disease |  | ||||
UCB0107 | anti-Tau antibody |  | ||||
| Immunology | Indications | Phase 1 | Phase 2 | Phase 3 | Filed | |
|---|---|---|---|---|---|---|
| bimekizumab (IL17AF) | psoriasis |  | ||||
| psoriatic arthritis |  | |||||
| axial spondyloarthritis | | |||||
| dapirolizumab pegol (CD40L antibody)** | systemic lupus erythematosus |  | ||||
| rozanolixizumab / UCB7665 | myasthenia gravis | | ||||
| immune thrombocytopenia | | |||||
| chronic inflammatory demyelinating polyneuropathy (CIDP) |  | |||||
| UCB7858 / UCB0159 | auto-inflammatory diseases | | ||||
| Bone Health | Indications | Phase 1 | Phase 2 | Phase 3 | Filed | |
|---|---|---|---|---|---|---|
Evenity™ | osteoporosis in patients at high risk of fracture (Europe) |  | ||||
| * ** | In collaboration with Amgen - Launched in Japan / USA In collaboration with Biogen |
Information provided on this pages represents molecules currently under investigation and are not approved by any health authority worldwide.